Glioblastoma (GBM), one of the most malignant human neoplasias, responds poorly to current treatment modalities, with temozolomide (TMZ) being the drug most frequently used for its treatment. Tetra-O-methyl Nordihydroguaiaretic Acid (M4N) is a global transcriptional repressor of genes dependent on the Sp1 transcription factor, such as Survivin and Cdk1. In the present study we evaluated the gene expression of Survivin, its spliced variants and Cdk1 in GBM samples and cell lines. Moreover, we investigated the effects of M4N combined or not with TMZ and/ or radiation on GBM primary cultures and cell lines. qRT-PCR assays were performed to determine the Survivinspliced variants and Cdk1 gene mRNA expression in GBM tumor samples and cell lines. Cell proliferation was measured by XTT assay and cell cycle and apoptosis were determined by flow cytometry. Drug combination analyses using different schedules of administration (simultaneous and sequential) were performed on GBM cell lines and primary cultures based on the Chou-Talalay method. For clonogenic survival, doses of 2, 4, and 6 Gy of gamma radiation. were used. All Survivin-spliced variants and the Cdk1 gene were expressed in GBM samples (n=16) and cell lines (n=6), except the Survivin-2B variant that was only expressed in GBM cell lines. M4N treatment down regulated the expression of Cdk1, Survivin and the Survivin-ΔEx3 variant, while the Survivin-2B variant was up-regulated. M4N decreased the cell proliferation separately and synergistically with TMZ, and enhanced the effects of radiation, mainly when associated with TMZ. M4N also induced apoptotic cell death, decreased the mitotic index and arrested the cell cycle mainly in the G2/M phase. Our results suggest a potential clinical application of M4N in combination with TMZ and radiation for GB treatment.
12-15 months [3] . Currently, temozolomide (TMZ) is the main drug used for GBM therapy, acting through alkylation at the 0-6 position of guanine. Both TMZ and RT therapy can induce DNA damage; however their efficacy is hindered in part by alterations in the apoptotic and cell cycle mechanisms of cancer cells [4, 5] , which are becoming promising targets for the development of novel and more efficient therapeutic agents.
Survivin protein has been considered an ideal target for cancer treatment due to its high and unique expression in most human tumors and its critical role in the control of cell division and inhibition of apoptosis [6] [7] [8] [9] [10] . Its high expression in malignant brain tumors, particularly GBM [11] , has been strongly associated with a poor prognosis and resistance to chemo-and radiotherapy [12, 13] , suggesting that survivin represent a promising target for GBM therapy. Moreover, several Survivin splice variants such as Survivin-ΔEx3 and Survivin-2B have also been identified in GBM thus far and little is known about their function in these cells.
A critical necessity for survivin to perform its role efficiently during mitotic processes is phosphorylation by cyclindependent kinase 1 (Cdk1) [14] . Cdk1 is a master modulator in the initiation and transition process through mitosis during the cell cycle [15] . The high expression and activity of Cdk1 protein is often observed in several human cancers [16, 17] and is associated with tumor progression [18] , including GBM [19] , suggesting Cdk1 as a promising target for GBM treatment.
Tetra-o-methyl nordihydroguaiaretic acid (also known as M4N, terameprocol, and EM1421) blocks cell cycle progression by inhibiting the expression of the Cdk1 gene [20] and simultaneously promotes apoptosis by inhibiting the expression of the Survivin gene [21] . Recently, a Phase I clinical trial in patients with recurrent high-grade gliomas showed adequate pharmacokinetic tolerance and a promising anti-tumor activity. However, this previous study recommended the conduction of preclinical studies of combined therapy with TMZ and RT prior to initiating human studies of toxicity and efficacy [22] .
The aim of the present study was to evaluate the gene expression of Survivin variants and Cdk1 gene in GBM tumor samples and cell lines. Moreover, we demonstrated the potent anti-GBM activity of M4N in both GBM cell lines and primary cultures, as well as its synergistic effects when combined with TMZ and RT. Additionally, our study shows that M4N deregulated the cell cycle, caused apoptosis, and altered gene expression in GBM cell lines.
Material and methods

Patients
Twenty six fresh-frozen microdissected tumor samples were obtained from macrodissected glioblastomas according to the WHO classification [23] , from subjects admitted for diagnosis and treatment to the University Hospital of the School of Medicine of Ribeirão Preto, SP, Brazil. Six samples of microdissected non-neoplastic brain tissue (white matter) were obtained from patients who had undergone surgery for the treatment of epilepsy. The average age of the patients was 44.3 years and three subjects were pediatric patients. Ten subjects were men and 6 were women. The study was approved by the Institutional Research Ethics Committee (protocol number 8608/2009).
Cell culture and primary culture
Human adult GBM cell lines (U251, U343, T98G, U87, LN319) and a pediatric GBM cell line (SF188) were obtained and grown as previously described [24] . The GBM primary cultures (GBPCs) were derived from biopsy specimens of GBM patients under a protocol approved by the institutional review board of the University Hospital, School of Medicine of Ribeirão Preto, SP, Brazil. Cultures were obtained according to Brassesco et al. [25] and maintained at low passage numbers (p2-p6) under standard culture conditions. Reagents M4N was purchased from Cayman Chemical Co. (Ann Arbor, MI, USA, #70302). M4N was dissolved in dimethylsulfoxide (DMSO; Mallinckrodt Chemical Works, St Louis, MO, USA) at 50 mM. A stock solution was then warmed to 70°C for 3 h as recommended by Chang et al. [21] , before the addition to the cell culture medium at a final DMSO concentration of 1 %. TMZ (Sigma-Aldrich, São Paulo, Brazil) was also diluted in DMSO at a stock concentration of 200 mM. Stock solutions were kept at − 20°C and dissolved in culture medium immediately before the experiments.
RNA isolation and reverse transcription-PCR mRNA was extracted from cell lines and tumor samples using the Trizol® reagent (Gibco BRL, Life technologies®, Carlsbad, CA, USA). Complementary DNA (cDNA) was obtained with the High Capacity® kit (Applied Biosystems®, Foster City, CA, USA) according to the manufacturers' instructions. cDNA levels of the Survivin, Survivin-2B, Survivin-ΔEx3, and Cdk1 genes were measured using an ABI 7500 Real Time PCR System (PE Applied Biosystems). Amplifications were obtained using TaqMan® probes: Survivin (Hs00977612_mH), Survivin-2B (Hs03043575_m1), Survivin-deltaEx3 (Hs03043576_m1), Cdk1 (Hs00938777_m1), TBP (4326322E0811008), and HPRT (4310809E0502006) (Applied Biosystems). The relative expression was calculated using the 2 -ΔΔCT method [26] with two internal controls, TBP and HPRT, as recommended by Valente et al. [27] . To determine the effects of M4N on survivin gene expression, their spliced variants and Cdk1 gene, the cell lines SF188, T98G, U251, and U343 were treated with 40 μM of M4N for 6, 12, and 24 h. In these experiments, control cells (DMSO) collected at the same treatment times were used as calibrators.
Growth inhibition assays
Growth inhibition was determined by two proliferation assays: XTT-assay and/or Giemsa-staining of attached cells as previously published [24, 28] . SF188, T98G, U251, and U343 cells were seeded at 3×10 3 cells/well in 96-well plates. After attachment, cells were treated with serial doses of M4N or TMZ for 24, 48, and 72 h. Similarly, eleven GBPCs were treated for 48 h with M4N, and four of them were additionally treated with M4N or TMZ for 96 h. The IC 50 (the drug concentration that inhibits cell proliferation by 50 % compared with controls) was calculated using CalcuSyn software (Biosoft, Ferguson, Missouri, USA).
Combination drug analysis
The interaction between M4N and TMZ was analyzed using Calcusyn. For the analyses of combinations, increasing doses of each drug were used according to their equipotent molar ratio for each cell line through three different exposure schedules: simultaneous, sequential with TMZ after M4N, and sequential with M4N after TMZ. For GBPCs, similar exposures were performed using the fixed doses of 20 μM or 40 μM M4N, and 500 μM TMZ. Treatments of 48 h or 96 h were used for simultaneous exposure of cell lines and GBPCs, respectively. For sequential exposure, the treatments with each drug were for 24 h and 48 h for the cell lines and GBPCs, respectively. Combination indexes (CIs) were generated for each set of combinations and synergistic (CI<1), additive (CI=1), or antagonistic effects (CI>1) were calculated by the Chou and Talalay equation [29] using Calcusyn software. The dose reduction index (DRI) represents the measure of how much the dose of each drug in a synergistic combination may be reduced at a given effect level compared with the dose of each drug alone [29] .
Clonogenic assay
The effects of M4N and TMZ on clonogenic capacity were evaluated according to Franken's protocol [30] . Single cell suspensions of 300 cells/well were seeded in six-well plates and, once attached, were treated with serial concentrations of M4N or TMZ for 48 h. After treatment, the culture medium was exchanged with a drug-free medium for incubation for 7-10 days. Next, surviving colonies were fixed with methanol and stained with Giemsa. The colonies with more than 50 cells were scored. These data were used to calculate the relative survival fraction and clonogenic IC 50 values (concentration for the reduction of 50 % survival fraction) calculated using the Calcusyn software. The IC 50 values for each drug were used for combination experiments. Cells were treated with M4N, TMZ, or M4N+TMZ for 48 h and then irradiated, cultured, and further analyzed as described by Borges et al. [24] . In all cases, three independent experiments were performed.
Apoptosis assessment, cell cycle analysis and mitotic index determination
Cells were treated with M4N for 48 h and apoptotic cell death was determined as previously reported [28] . For cell cycle analysis, sub-confluent cultures were exposed to 40 μM M4N (SF188 and T98G cells) or 20 μM M4N (U251 and U343 cells) for 24 h. Cells were trypsinized, washed with 1X PBS, and stained with propidium iodide (PI) using the CycleTEST TM PLUS DNA reagent kit (Becton Dickinson Immunocytometry Systems, San Jose, CA). The cell DNA content was immediately analyzed using a FACSCalibur apparatus (Becton Dickinson, Lincoln Park, NJ, USA). The percentages of cells in each cell cycle phase were calculated using ModFit LT software (Verity Software House, Topsham, ME, USA). For apoptosis and cell cycle assays at least 10,000 cells were measured per experiment. For mitotic index determination, exponentially growing cultures were treated with 0-80 μM M4N for 48 h and harvested as previously described [28] . In all cases, three independent experiments were performed.
Statistical analysis
Statistical analysis for gene expression was performed using the Mann-Whitney non-parametric test. For the functional studies, one-way or two-way ANOVA was used, followed by the nonparametric Bonferroni test, as appropriate. The effect of M4N and its combinations on colony formation was tested by logistic regression. Statistical significance was considered when P<0.05. Data analysis was carried out using the SPSS17.0 statistical software package (SPSS, Chicago, IL, USA). Results are reported as means±SD.
Results
Expression of survivin-spliced variants and CDK1 in GBM samples and cell lines
We found that Survivin, Survivin-ΔEx3 and Cdk1 were significantly expressed in tumor samples, while survivin-2B expression did not differ significantly from normal samples ( Fig. 1a-d ). We also found that all survivin splice variants were expressed in all cell lines, with the Survivin variant being the one most expressed in cell lines, mainly in SF188 and U251 cells. The Cdk1 gene expression was found in all cell lines, mainly in SF188 and U343 cells ( Fig. 1e ).
M4N inhibited cell proliferation of GBM cell lines
The SF188, T98G, U251 and U343 cells were sensitive to M4N, showing inhibited growth in a dose-and timedependent manner (p<0.05) except for SF188 cells that only displayed a dose-dependent inhibition (p=0.009) ( Fig. 2ad) . The 48 h-IC 50 values corroborated the remarkable sensitivity of T98G, U251 and U343 cells, and a relative resistance of SF188 cells (Table 1) . To expand the relevance of our findings, we assessed the response of GBPCs to M4N. A total of eleven GBPCs were included in the analysis exhibiting a variety of IC 50 values at 48 h (18.4 -282.2 μM). We found that most GBPCs showed a dosedependent response to M4N ( Fig. 2e , Table 2 ). The M4N-IC 50 values were drastically diminished in four GBPCs after M4N-treatment for 96 h (GB27, GB28, GB45, and GB49) ( Table 2 ). Our results demonstrate that M4N was efficient in inhibiting the proliferation of GBM cells.
Additionally, the chemosensitivity of cell lines and GBPCs to TMZ was determined by drug combination assays (Supplementary Data Fig. S1-S2 ). The IC 50 values obtained showed high sensitivity to TMZ of U251 and U343 Fig. 1 Survivin, Survivin-2B, Survivin-ΔEx3 and Cdk1 mRNA expression in the samples of glioblastoma tumor and cell lines. Relative expression levels of Survivin (a), Survivin-2B (b), Survivin-ΔEx3 (c) and Cdk1 (d) are shown in glioblastoma samples [GBM samples] (n=16) and non-neoplastic brain tissue [NT] (n=6). The relative expression levels of the same genes in six cell lines are shown (e). Expression levels are displayed as a ratio between the target genes and two reference genes (TBP and HPRT) to correct for variation in the amounts of RNA. The line corresponds to the median value (a-d). The p values are shown to indicate statistical differences cells and a relative resistance of SF188 and T98G cells ( Table 1) . Taken together, these data showed molar ratios proportional to IC 50 values as 1:25 (M4N:TMZ) for SF188 and T98G, and 1:9.375 (M4N:TMZ) for U251 and U343. Table S1 ). Figure 3 illustrates the schedule-dependent synergism between M4N and TMZ. Simultaneous exposure to both drugs (M4N+TMZ) for 48 h resulted in synergism in all cell lines and in all the ranges of affected fractions (CI<1, Fig. 3a-d) , except for the T98G cell line that showed a synergistic effect only up to 65 % of the Fig. 3 Sequence-dependent interactions between M4N and TMZ in SF188, T98G, U343 and U251 cells in vitro. Plots of the combination index (CI) from glioblastoma cell lines exposed to M4N and TMZ using different schedules of administration: simultaneous 48h exposures (a-d); sequential M4N→TMZ exposures, 24-h each (eh); and sequential TMZ→M4N exposures, 24-h each (i-l) at different molar ratios of the two agents (M4N:TMZ). The line across the CI value of 1 indicates additivity; CIs above and below indicate antagonism and synergism, respectively. Crosses represent the CIs of the actual data points and continuous lines represent computer-derived CIs at effect levels ranging from 10 to 100 % inhibition of clonal growth according with Calcusyn software affected fraction (Fig. 3b) . Similarly, the TMZ→M4N sequence mainly showed synergistic effects in all affected fractions in all cell lines (CI < 1; Fig. 3i-l) . The sequential M4N→TMZ exposure produced antagonistic effects in T98G and U251 cells in all the ranges of the affected fraction (CI>1, Fig. 3f, h) , while in SF188 it produced antagonistic effects only in up to 35 % of the affected fraction (Fig. 3e) , and in U343 cells it produced synergistic effect in up to 75 % of the affected fraction (Fig. 3g) .
We also performed drug combination assays on four GBPCs using 20 μM (GB45 and GB49) or 40 μM (GB27 and GB28) M4N and 500 μM TMZ with the same three different schedules described above (Fig. 4) . As found in cell lines, we detected significant differences between drug treatment with each drug separately and the combination of both in simultaneous exposure and sequential TMZ→M4N exposure (GB27 and GB49), whereas the inverse M4N→TMZ sequence did not produce statistical differences in these cells (Fig. 4a,  d) . For GB28 cells, all the three drug combination modes resulted in greater cytotoxicity than obtained with TMZ and M4N alone (Fig. 4b) . Conversely, in GB45 cells we did not detect statistical differences between separate treatment with each drug and treatment with drug combinations (Fig. 4c) .
Taken together, these data suggest that the combination of M4N and TMZ caused a synergistic effect in GBM cells preferentially when simultaneous combination or sequential TMZ→M4N exposure was used.
M4N enhanced the response to radiation in glioblastoma cell lines, especially when combined with TMZ After the determination of clonogenic IC 50 values for each drug (Supplementary Data Fig. S3 ), combination assays with both drugs (IC 50 ) and radiation was performed. M4N alone significantly enhanced the radiosensitivity of only U343 cells (p<0.001) ( Supplementary Data Fig. S4 ). On the other hand, the combination of M4N with TMZ significantly enhanced the effects of radiation in all cell lines when compared to each drug alone (Fig. 5 ). The strongest effect was achieved with the highest irradiation dose (6 Gy) in all cell lines, as indicated by dose enhancement ratios of 6.33, 1.59, 5.29, and 5.01 for SF188, T98G, U251, and U343 cell, respectively (Table 3) . Thus, M4N treatment is able to sensitize GBM cell lines to radiation and may increase the radiosensitization caused by TMZ.
M4N caused apoptotic cell death, altered the cell cycle and decreased the mitotic index in GBM cell lines
The number of apoptotic cells increased in M4N-treated cells (annexin-V-positive cells) in a dose-dependent manner. The strongest effect was obtained with 30 μM M4N, mainly in SF188 and T98G cells, with 92 % and 90 % of apoptotic cells, respectively (Fig. 6a) . Moreover, M4N significantly decreased the mitotic index in GBM cell lines (Fig. 6b) . Although the strongest effect was obtained with 80 μM M4N in U343, U251 and T98G cells (90 %, 94 % and 72 %, respectively), only a 62 % decrease was achieved in the SF188 cell line with this concentration (Fig. 6b) . Additionally, as shown in Fig. 6d-f, M4N induced a small, but significant, increase in the number of cells in the G2/M phase in the T98G, U251 and U343 cell lines (a 6 %, 3.5 % and 5 % increase, respectively). In contrast, treatment with 40 μM M4N induced a significant arrest in the G0/G1 phase in the SF188 cell line (Fig. 6c ) with a 17 % increase of the G0/G1 population, accompanied by a 13 % reduction of the S-phase population.
Effect of M4N on gene expression in GBM cell lines
Furthermore, gene expression in SF188, T98G, U251 and U343 cells was investigated after M4N treatment at 6, 12 and 24 h by qRT-PCR procedures (Fig. 7) . M4N (40 μM) down-regulated Survivin mRNA levels in a time-dependent manner in T98G, U251 and U343 cells, with the strongest effect at 24 h (17 %, 30 % and 46 % of control, respectively). Although down-regulation of this splice variant was not statistically different in SF188 cells, we observed a tendency toward significance. Moreover, M4N also decreased mRNA levels of the Survivin-ΔEx3 gene variant and Cdk1 gene in U251 and U343 cells at 24 h. Interestingly, M4N caused a significant increase of Survivin-2B expression in T98G cells (p< 0.001), a tendency toward it in SF188 cells, and a decreased expression of this gene variant in U343 cells (Fig. 7) .
Discussion
GBM is an aggressive tumor for which efficient treatment options are limited and new therapies with novel mechanisms of action are urgently required [1, 31, 32] . Currently, molecules that are differentially expressed in cancer and intersect multiple pathways required for tumor maintenance are considered better choices for targeted cancer therapy [33, 34] . The anti-apoptotic Survivin and the main regulator of the cell cycle Cdk1 embody these properties and Fig. 5 M4N enhanced the radio-sensitizing effects of TMZ in glioblastoma cell lines. SF188 (a), T98G (b), U251 (c), and U343 (d) glioblastoma cell lines were treated with clonogenic IC 50 values of TMZ (white square) or M4N+TMZ (black square) for 48 h and then exposed to radiation (0-6 Gy). After 7-10 days, colonies were stained and scored. Values shown are the means±SD of three separate experiments. The P values for clonogenic survival obtained by linear regression are shown Highlighted in bold DER values statistically different obtained by linear regression as described previously in Material and Methods represent important molecules for target-specific therapy of many tumors, including GBM [31, 35, 36] .
In this study, we report for the first time an investigation of the effects of M4N, a transcriptional inhibitor of Sp1dependent genes, such as Survivin and Cdk1, on GBM cells. Here, we analyzed the gene expression of Survivin and its splice variants: Survivin-ΔEx3 and Survivin-2B, as well as of the Cdk1 gene in GBM tumor samples, GBM cell lines, and normal samples by using quantitative qRT-PCR. To date, only one successful quantitative analysis of Survivin splice variants using TaqMan qRT-PCR in GBM samples has been reported [37] . Like Yamada et al. [37] , we found that Survivin and Survivin-ΔEx3 mRNA expression was significant in GBM samples and cell lines, while that gene expression of Survivin-2B in GBM tumor samples did not differ from normal samples. Moreover, we also showed higher Cdk1 mRNA expression in all GBM tumor samples and cell lines than in normal samples, similarly to Chen, et al. [19] . All of these data provide enough evidence to evaluate both these targets as potential alternatives for GBM treatment.
We also found that M4N acted efficiently by inhibiting cell growth in cell lines and GBPCs. Since primary tumor cultures are believed to reflect more accurately the in vivo tumors than established cancer cell lines [24, 38] , we considered the anti-growth activity of M4N on these cells to have been highlighted. The growth inhibitory effects of M4N on cancer cells lines and various kinds of xenograft tumors have been reported elsewhere [39] [40] [41] [42] [43] [44] [45] . Our study indicates that GBM is an additional promising target for M4N therapy.
We performed drug combination assays with M4N and TMZ using three different strategies of administration schedule in cell lines and four GBPCs. We observed that both simultaneous combination (M4N+TMZ) and sequential treatment (TMZ→M4N) exhibited synergistic effects while the reverse sequence (M4N→TMZ) yielded a preferential antagonistic effect. The antagonism resulting from M4N→TMZ could be explained by the recovery of growth caused by removal of M4N [21] , together with activation of mechanisms of TMZ-mediated cell resistance such as upregulation of Survivin [46] . Interestingly, the combination results obtained in this study permitted us to demonstrate not only a potent chemo-sensitizing effect of M4N when simultaneously combined with TMZ, but also to recognize the critical importance of the sequence of chemotherapeutic drug administration in terms of antitumor efficacy [47] , as demonstrated by the synergistic TMZ→M4N combination.
Our investigation also evaluated the radio-sensitizing potential of M4N using clonogenic assays. We found that M4N treatment alone significantly enhanced the sensitivity to radiation of the U343 cell line (the only p53 proficient one). It is known that radiation-mediated DNA damage stabilizes p53 protein and consequently activates its role as a transcriptional repressor of Survivin [48, 49] . Thus, p53- The cell lines were treated for 6, 12, and 24 h with 40 μM M4N. The level of expression of the different mRNAs was assessed by qRT-PCR as reported in Materials and methods and displayed as a ratio between the target genes and two reference genes (TBP and HPRT) to correct for variation in the amounts of RNA. Cells treated with vehicle alone (Control) collected at the same treatment times were used as calibrators. Data are the mean ± SE of three independent experiments. *P<0.05; **P<0.01; ***P<0.001 proficient cells that are able to block survivin transcription could be more susceptible to the M4N→radiation combination, whereas p53-deficient cells such as SF188, T98G, and U251 cells [50] are M4N-resistant, as demonstrated in the present study. However, a different drug administration schedule could overcome this resistance mechanism, as done by Sun, et al. [51] who administered radiation to non-small cell lung carcinoma followed by M4N treatment (radiation→M4N). Thus, we believe that the radiosensitizing effect of M4N could be schedule-and p53 status-dependent.
Interestingly, the combination of M4N and TMZ significantly enhanced the sensitivity of all GBM cell lines to RT when compared to drug treatment alone. It has been previously demonstrated that survivin inhibition by other strategies enhanced the radiosensitivity of cancer cells [52] [53] [54] [55] . However, this is the first description of the radiosensitization caused by the combination of M4N and a chemotherapeutic agent.
M4N treatment of several human tumor cells in vitro and xenograft models results in induction of apoptosis by suppressing the Survivin gene and in the arrest of the cell cycle associated with diminished expression of Cdk1 [21, 41, 51] . Thus, although resistance to apoptosis is intrinsically characteristic of GBM [56, 57] , M4N was able to induce apoptosis in a dose-dependent manner in all GBM cell lines, mainly in SF188 cells. In addition, we evaluated the cell cycle changes and found a mild, but significant, increase of the cell population in the G2/M phase in T98G, U251, and U343 cells after 24-h M4N treatment. Interestingly, the SF188 cell line displayed a particular response with an increased cell population in the G0/G1 phase and a lower reduction of the mitotic index when compared to other cell lines.
The SF188 cell line showed the highest levels of both Survivin and Cdk1 gene expression, as well as an elevated proliferative resistance to M4N when compared to the T98G, U343 and U251 cell lines, probably due to less profound down-regulation of Survivin and Cdk1 transcription in SF188 cells. Nevertheless, SF188 showed high M4N-mediated apoptotic sensitivity and the strongest synergistic effect when combined with TMZ compared to other cell lines. All of these interesting differences between this SF188 pediatric GBM cell line and adult cell lines shown here are consistent with several lines of clinical and molecular evidence suggesting that pediatric GBMs are indeed different from adult GBMs [58] [59] [60] .
We also report that M4N decreased mRNA levels of Survivin-ΔEx3 in U251 and U343 cells and significantly increased Survivin-2B mRNA in T98G cells. Although these interesting data could contribute to the view that Survivin-ΔEx3 plays a positive role in inhibiting apoptosis while Survivin-2B acts as a pro-apoptotic factor [8, [61] [62] [63] [64] [65] , the down regulation of Survivin-2B observed in M4N-treated U343 cells (p53 proficient) suggests that these concepts are still controversial [66, 67] .
In conclusion, this study showed that M4N induced growth arrest and apoptosis of GBM cells. Furthermore, drug combination analysis supported the potential of M4N as a chemo-and radio-sensitizing agent in GBM, suggesting rational administration schedules that may be of clinical use in GBM therapy. Moreover, our data also indicate biological differences between pediatric and adult GBM cells related to their response levels. On this basis, we propose that M4N may be a promising tool for adjuvant therapy and for enhancing the efficacy of conventional treatment modalities for GBM.
